A detailed history of Shikiar Asset Management Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Shikiar Asset Management Inc holds 15,750 shares of ALLO stock, worth $29,452. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,750
Previous 15,750 -0.0%
Holding current value
$29,452
Previous $37,000 18.92%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 20, 2023

SELL
$4.53 - $6.74 $33,975 - $50,550
-7,500 Reduced 32.26%
15,750 $78,000
Q4 2021

Jan 21, 2022

SELL
$13.13 - $24.52 $20,154 - $37,638
-1,535 Reduced 6.19%
23,250 $347,000
Q3 2021

Oct 29, 2021

SELL
$21.01 - $27.64 $65,131 - $85,684
-3,100 Reduced 11.12%
24,785 $637,000
Q2 2021

Jul 16, 2021

BUY
$23.49 - $35.8 $72,819 - $110,979
3,100 Added 12.51%
27,885 $727,000
Q1 2021

May 05, 2021

SELL
$25.79 - $39.02 $270,795 - $409,710
-10,500 Reduced 29.76%
24,785 $875,000
Q4 2020

Feb 03, 2021

BUY
$25.24 - $43.45 $127,714 - $219,857
5,060 Added 16.74%
35,285 $891,000
Q3 2020

Oct 28, 2020

SELL
$32.38 - $44.96 $3,238 - $4,496
-100 Reduced 0.33%
30,225 $1.14 Million
Q2 2020

Aug 20, 2020

BUY
$18.39 - $54.04 $36,780 - $108,080
2,000 Added 7.06%
30,325 $1.3 Million
Q1 2020

May 01, 2020

SELL
$18.22 - $28.25 $133,370 - $206,790
-7,320 Reduced 20.54%
28,325 $551,000
Q4 2019

Jan 28, 2020

BUY
$24.82 - $31.4 $16,133 - $20,410
650 Added 1.86%
35,645 $926,000
Q3 2019

Oct 29, 2019

SELL
$26.11 - $32.99 $219,324 - $277,116
-8,400 Reduced 19.36%
34,995 $954,000
Q2 2019

Jul 25, 2019

SELL
$25.56 - $31.09 $214,448 - $260,845
-8,390 Reduced 16.2%
43,395 $1.17 Million
Q1 2019

Apr 30, 2019

BUY
$24.82 - $32.54 $312,359 - $409,515
12,585 Added 32.1%
51,785 $1.5 Million
Q4 2018

Feb 01, 2019

BUY
$22.5 - $33.3 $882,000 - $1.31 Million
39,200 New
39,200 $1.06 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $269M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Shikiar Asset Management Inc Portfolio

Follow Shikiar Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shikiar Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Shikiar Asset Management Inc with notifications on news.